Exopolysaccharide from Lactobacillus rhamnosus ZFM231 alleviates DSS-induced colitis in mice by regulating gut microbiota.
C. Wan,Q. Gu,Xiao-Lin Wang,Tao Zhou,Meng Tang,Ping Li,Wen-Wen Qian,X. Pi,W. Liu
DOI: https://doi.org/10.1002/jsfa.12070
2022-06-16
The Journal of the Science of Food and Agriculture
Abstract:BACKGROUND
The exopolysaccharides (EPS) produced by Lactobacillus and other probiotics are associated with many benefits, such as immune regulation, antioxidant properties, antitumor effect, and regulation of intestinal microbe homeostasis. In the present work, the modulatory effect of EPS produced by Lactobacillus rhamnosus ZFM231 on the intestinal flora of mice with inflammatory bowel disease (IBD) induced by dextran sulfate solution (DSS) was investigated.
RESULTS
Results indicated that weight loss, colonic length, the disease activity index (DAI) score and colonic tissue damage in mice were significantly improved by EPS treatment. Compared with the model group, in the EPS-treated group, the diversity of and composition of gut microbiota at both phylum and genus levels were found to recover to the levels of normal group, indicating the effective modulation on gut microbiota by EPS; short-chain fatty acids (SCFAs), including acetic acid, propionic acid and butyric acid produced by intestinal microbial metabolism, increased significantly; the level of anti-inflammatory factor TGF-β significantly increased and the level of pro-inflammatory factor TNF-α significantly decreased in the colonic cells of EPS-treated mice.
CONCLUSION
It is clear that EPS produced by L. rhamnosus ZFM231 could find application in functional foods with the property of anti-ulcerative colitis. The experimental results provide new insights into the probiotic effect of EPS. This article is protected by copyright. All rights reserved.
Medicine,Biology,Environmental Science